Abstract
The in vitro activity of biapenem was compared to that of imipenem, meropenem and other broad-spectrum beta-lactams. A total of 716 isolates from recent cases of clinical septicemia and an additional 137 stock strains possessing known beta-lactamases or other well-characterized resistance mechanisms were tested. The minimal concentrations inhibiting 90 % of strains (MIC90) ofEnterobacteriaceae species were for biapenem 0.03 to 1 mg/l and for imipenem 0.25 to 2 mg/l. No member of theEnterobacteriaceae was found to be resistant to biapenem. Biapenem and meropenem were the most active drugs againstPseudomonas aeruginosa, with an MIC90 of 1 mg/l. Biapenem was more active than ceftazidime against most gram-negative and gram-positive bacteria tested. Biapenem was as potent as imipenem against anaerobic bacteria (includingBacteroides fragilis), with an MIC90 of 0.25 mg/l. High MICs of biapenem were demonstrated forXanthomonas maltophilia, oxacillin-resistantStaphylococcus spp. andEnterococcus spp. These species have demonstrated resistance to other carbapenems and to most of the newer cephalosporins. The results of this study, coupled with previously documented favorable qualities of biapenem, endorse further investigation of this broad-spectrum antibacterial agent for clinical use.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kahan JS, Kahan FM, Goegelman R, Currie MJ, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, Hernandez S, Woodruff HB, Birnbaum J Thienamycin, a new β-lactam antibiotic. I: Discovery, taxonomy, isolation and physical properties. Journal of Antibiotics 1979, 32: 1–12.
Wise R In vitro and pharmacokinetic properties of the carbapenems. Antimicrobial Agents and Chemotherapy 1986, 30: 343–349.
Jones RN Review of the in vitro spectrum of activity of imipenem. American Journal of Medicine 1985, 78, Supplement 6A: 22–40.
Birnbaum J, Kahan FJ, Kropp H, MacDonald JS Carbapenems, a new class of beta-lactam antibiotics. American Journal of Medicine 1985, 78, Supplement 6A: 3–21.
Moellering RC, Eliopoulus GM, Sentochnik DE The carbapenems: new broad spectrum beta-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 1–7.
Kropp H, Sundelof G, Hajdu R, Kahan FM Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrobial Agents and Chemotherapy 1982, 22: 62–70.
Hikida M, Kawashima K, Nishiki K, Furukawa Y, Nishizawa K, Saito I, Kuwao S Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic. Antimicrobial Agents and Chemotherapy 1992, 36: 481–483.
Peterson PJ, Jacobus NV, Weiss WJ, Testa RT In vitro and in vivo activities of LJC 10,627, a new carbapenem with stability to dehydropeptidase I. Antimicrobial Agents and Chemotherapy 1991, 35: 203–207.
Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, Kuonno M, Mitsuhashi S In vitro activity of LJC 10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrobial Agents and Chemotherapy 1990, 34: 994–1000.
Catchpole CR, Wise R, Thomber D, Andrews JM In vitro activity of L-627, a new carbapenem. Antimicrobial Agents and Chemotherapy 1992, 36: 1928–1934.
Yoshida M, Mitsuhashi S In vitro activity and beta-lactamase stability of the new carbapenem LJC 10,627. European Journal of Clinical Microbiology & Infectious Diseases 1990, 9: 625–629.
Neu HC, Gu JW, Fan W, Chin NX In vitro activity and beta-lactamase stability of LJC 10,627. Antimicrobial Agents and Chemotherapy 1992, 36: 1418–1423.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 2nd ed. Approved standard, M7-A2. NCCLS, Villanova, PA, 1990.
Jorgensen JH, Redding JS, Maher LA, Howell AW Improved medium for antimicrobial susceptibility testing ofHaemophilus influenzae. Journal of Clinical Microbiology 1987, 25: 2105–2113.
Jorgensen JH, Maher LA, Howell AW Use of Haemophilus Test Medium for broth microdilution antimicrobial susceptibility testing ofStreptococcus pneumonia. Journal of Clinical Microbiology 1990, 28: 430–434.
Jones RN, Gavan TL, Thornsberry C, Fuchs PC, Gerlach EH, Knapp JS, Murray P, Washington JA Standardization of disk diffusion and agar dilution susceptibility tests forNeisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. Journal of Clinical Microbiology 1989, 27: 2758–2766.
National Committee for Clinical Laboratory Standards Methods for antimicrobial susceptibility testing of anaerobic bacteria, 2nd ed. Approved standard M11-A2. NCCLS, Villanova, PA, 1991.
Piddock LJV, Wijnands WJA, Wise R Quinolone/ureidopenicillin cross-resistance. Lancet 1987, ii: 907.
Legakis NJ, Tzouvelekis LS, Makris A, Kotsifaki H Outer membrane alterations in multiresistant mutants ofPseudomonas aeruginosa selected by ciprofloxacin. Antimicrobial Agents and Chemotherapy 1989, 33: 124–127.
Masuda N, Ohya S Cross-resistance to meropenem, cephems, and quinolones inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1992, 36: 1847–1851.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sader, H.S., Jones, R.N. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs. Eur. J. Clin. Microbiol. Infect. Dis. 12, 384–391 (1993). https://doi.org/10.1007/BF01964439
Issue Date:
DOI: https://doi.org/10.1007/BF01964439